The assertive approach to clozapine: nasogastric administration
| Autor: | Alex Till, Edward Silva, James Selwood |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Psychosis media_common.quotation_subject 03 medical and health sciences 0302 clinical medicine medicine Assertiveness 030212 general & internal medicine psychosis Psychiatry Clozapine media_common Psychotic disorders clozapine business.industry nasogastric administration medicine.disease Original Papers 030227 psychiatry schizophrenia Psychiatry and Mental health antipsychotics Schizophrenia Mental state business Administration (government) medicine.drug |
| Zdroj: | BJPsych Bulletin Till, A, Selwood, J & Silva, E 2019, ' The assertive approach to clozapine : Nasogastric administration ', BJPsych Bulletin, vol. 43, no. 1, pp. 21-26 . https://doi.org/10.1192/bjb.2018.61 |
| ISSN: | 2056-4708 2056-4694 |
| DOI: | 10.1192/bjb.2018.61 |
| Popis: | Aims and methodAn ‘assertive approach’ to clozapine, where nasogastric administration is approved, is assessed through a case-load analysis to provide the first systematic description of its use and outcomes worldwide.ResultsFive of the most extremely ill patients with treatment-resistant schizophrenia were established and/or maintained on clozapine, resulting in improvements to their mental state; incidents were reduced, segregation was terminated and progression to less restrictive environments was achieved.Clinical implicationsDespite being underutilised and rarely enforced, in extreme circumstances, an assertive approach to clozapine can be justified. Nasogastric clozapine can be safely delivered and the approach itself, rather than actual nasogastric administration, may be enough to help establish and maintain patients with treatment-resistant schizophrenia on the most effective treatment.Declaration of interestE.S. has received speaker fees from Jansen Pharmaceuticals and Novartis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|